跳至主要内容
临床试验/NCT02353351
NCT02353351终止不适用

Closure of Atrial Septal Defects With the AMPLATZER™ Septal Occluder (ASO) Post Market Surveillance Study

Abbott Medical Devices65 个研究点 分布在 1 个国家目标入组 602 人开始时间: 2015年1月19日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
602
试验地点
65
主要终点
Cumulative incidence of cardiac erosion

研究概览

简要总结

Prospective, multicenter, case-cohort study.To identify potential risk factors associated with the occurrence of erosion due to implantation of the AMPLATZER™ Septal Occluder (ASO.)

详细描述

This study will enroll 8000 subjects. The sub-cohort will consist of 160 (2%) subjects, randomly selected from the full cohort. The analysis population will consist of all subjects in the sub-cohort, combined with all subjects with erosion events who are not in the sub-cohort. A detailed assessment of risk factors will be conducted on the subjects in this analysis population.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • To participate in this clinical investigation, the patient must meet all of the following inclusion criteria:
  • Patient indicated for ASD closure who has echocardiographic evidence of ostium secundum atrial septal defect and clinical evidence of right ventricular volume overload (such as, 1.5:1 degree of left-to-right shunt or RV enlargement) and is implanted with the ASO device Note: This does not include the indication for closure of a fenestration following a fenestrated Fontan procedure
  • Patient is willing and able to complete the follow-up requirements of this study
  • Patient signs the informed consent (or a legal representative signs the informed consent.)

排除标准

  • Patient is not eligible for clinical investigation participation if he/she meets any of the following exclusion criteria:
  • Patient is known to have extensive congenital cardiac anomaly which can only be adequately repaired by way of cardiac surgery
  • Patient is known to have sepsis within 1 month prior to implantation, or any systemic infection that cannot be successfully treated prior to device placement
  • Patient is known to have a bleeding disorder, untreated ulcer, or any other contraindications to aspirin therapy (unless another anti-platelet agent can be administered for 6 months)
  • Patient is known to have a demonstrated intracardiac thrombus on echocardiography
  • Patient whose size (such as, too small for transesophageal echocardiography probe, catheter size) or condition (active infection, etc.) would cause the patient to be a poor candidate for cardiac catheterization
  • Patient has margins of defect that are less than 5 mm to the coronary sinus, AV valves or right upper lobe pulmonary vein

结局指标

主要结局

Cumulative incidence of cardiac erosion

时间窗: 1 year

Cumulative incidence of erosion will be reported as: • The number of erosions per 8000 subjects.

次要结局

  • Superior Vena Cava (SVC) Rim Measurements (< 5 mm, ≥ 5 mm)(1 year)
  • Inferior Vena Cava (IVC) Rim Measurements (< 5 mm, ≥ 5 mm)(1 year)
  • Device Size Implanted (< 18 mm, ≥ 18 mm)(1 year)
  • Body Surface Area (<1.5 m2 and ≥ 1.5m2)(1 year)
  • Other Evaluable Rim Measurements (< 5 mm, ≥ 5 mm)(1 year)
  • Ratio of Defect Size (Diameter) to Septal Length (< 0.5:1, ≥ 0.5:1)(1 year)
  • Ratio of Defect Size (Diameter) to Septal Width (< 0.5:1, ≥ 0.5:1)(1 year)
  • Device Impingement of the Aorta (Yes, No)(1 year)
  • Device Abutting the Aorta (Yes, No)(1 year)
  • Age (< 14, ≥ 14 years)(1 year)
  • Aortic Rim Measurements (< 5 mm, ≥ 5 mm)(1 year)
  • Atrio-Ventricular (AV) Valve Rim Measurements (< 5 mm, ≥ 5 mm)(1 year)
  • Device Splaying the Aorta (Yes, No)(1 year)
  • Gender (Male, Female)(1 year)
  • Device Size to Defect Size (< 1.5:1, ≥ 1.5:1)(1 year)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (65)

Loading locations...

相似试验

ADVANCE ASO AMPLATZER™ Atrial Septal Occluder Post... | 临床试验